Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral and liver diseases, announced on April 16, 2026, that it has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech.
The partnership centers on the development and commercialization of Aligos’ lead chronic Hepatitis B (CHB) candidate, pevifoscorvir sodium (AL-3333), within Greater China.
Under the terms of the agreement, Aligos will receive an immediate upfront payment of $25 million.
The deal also includes potential development, regulatory, and commercial milestone payments totaling up to $420 million, in addition to tiered high single-digit royalties on future net sales within the territory.
Amoytop will be responsible for all costs associated with the development, clinical trials, and commercialization of the drug in Greater China, while Aligos retains full rights to the candidate in all other global markets.
Pevifoscorvir sodium is a liver-targeted prodrug of a potent Hepatitis B virus (HBV) polymerase inhibitor.
By partnering with Amoytop—a company with deep regional expertise and a strong track record in the Chinese hepatology market—Aligos aims to accelerate the delivery of this potential treatment to one of the world's largest patient populations affected by chronic HBV.
The non-dilutive capital from this transaction significantly strengthens Aligos’ financial position.
Management noted that the upfront payment, combined with existing resources, is expected to extend the company’s cash runway into the fourth quarter of 2026.